24/7 Wall Street
22 Sept 2026, 11:34 UTC · 1h ago
Verdict
Headline leans bullish. We score NVO −0.70 across five claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.70strongly bearish
What the story claims
5 claims · scored −1 bearish … +1 bullish · 1 new · 4 priced in
Citigroup analyst Geoff Meacham reiterated a Buy rating and set a Street-high price target of $1,600 for Eli Lilly.
Priced inanalysis of current trade and targets
So whatThis target represents a 37% upside from the current price of $1,164.79.
More positive than 92% of claims this week
Novo Nordisk shares fell 7.93% in a single session following a disappointing post-Wegovy strategy update on Monday.
Continue reading
5 related stories
More negative than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Newstrategy update on Monday
So whatPoor performance from the primary competitor may shift the 60% global market share assumption further toward Lilly.
More positive than 85% of claims this week
Eli Lilly's combined quarterly revenue from Mounjaro and Zepbound reached $14.9 billion.
Priced inanalysis of Q2 results reported earlier
So whatThe scale of these GLP-1s supports the TTM revenue of $79.67 billion.
More positive than 76% of claims this week
Eli Lilly targets a retatrutide BLA submission in Q1 2027.
Priced inno timing evidence
So whatA successful filing would be the primary driver for the projected 2027 EPS of $47.34.
More positive than 61% of claims this week
Realized U.S. prices for Lilly's products fell 9% excluding rebate adjustments.
Priced inanalysis of Q2 results reported earlier
So whatPricing compression threatens the current forward P/E of 24 if volume growth slows.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 84% of ticker scores this week
The stock dropped nearly 8% in one session after a strategy update disappointed investors.
More positive than 70% of ticker scores this week
The company crushed earnings estimates and has a high-conviction bull case from Citigroup despite recent stock price volatility.
More positive than 63% of ticker scores this week
Analysts see significant implied upside (207%) despite the inherent binary risks of clinical-stage biotech.
More negative than 72% of ticker scores this week
The stock is described as having underwhelming upside and ratings that lean toward 'Hold'.
More positive than 43% of ticker scores this week
Citigroup analysts are providing bullish price targets and research for the pharmaceutical sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 19% of relationship scores this week
[mutual] Viking Therapeutics is a clinical-stage biotech competing in the same obesity drug category as Eli Lilly.
More positive than 19% of relationship scores this week
[mutual] Both companies operate in the competitive obesity drug market.
—
NVO hasn't traded since this ran. Last close $39.82 (Sep 21); the reaction starts at the next open.
NVO chart →